DrugMapper


Trade Names:	VISIPAQUE 270 VISIPAQUE 320
Synonyms:	2-5410-3A 2-541O-3A Iodixanol NSC-760069 Visipaque Visipaque 270 Visipaque 320
Status:	Approved (1996)
Entry Type:	Unknown
Molecule Category:	UNKNOWN
ATC:	V08AB09
UNII:	HW8W27HTXX


InChI Key	NBQNWMBBSKPBAY-UHFFFAOYSA-N
Smile	CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I
InChI	InChI=1S/C35H44I6N6O15/c1-13(52)46(30-26(38)20(32(59)42-3-15(54)9-48)24(36)21(27(30)39)33(60)43-4-16(55)10-49)7-19(58)8-47(14(2)53)31-28(40)22(34(61)44-5-17(56)11-50)25(37)23(29(31)41)35(62)45-6-18(57)12-51/h15-19,48-51,54-58H,3-12H2,1-2H3,(H,42,59)(H,43,60)(H,44,61)(H,45,62)

Action	Mechanism of Action	Reference
None	Diagnostic agent	DailyMed

Mesh Heading	Maximum Phase	Mesh ID	Reference
Acute Kidney Injury	0	D058186	ClinicalTrials

Level 3

Level 4

Level 5

Level 6

Indication

Mechanism of Action

Primary Target

Target Level

Side effects	Relative Frequency (%)	Labels
Ear and labyrinth disorders Vertigo	28.3
Gastrointestinal disorders Dysgeusia	14.9
Scotoma	12.3
Nervous system disorders Headache	11.3
Nervous system disorders Sensory disturbance	6.6
Skin and subcutaneous tissue disorders Dermatitis	6.1
Skin and subcutaneous tissue disorders Rash	6.1
Gastrointestinal disorders Nausea	5.7
Nervous system disorders Headache	5.1
Gastrointestinal disorders Nausea	5.1
Cardiac disorders Chest pain	4.3
Skin and subcutaneous tissue disorders Pruritus	4.2
Nervous system disorders Confusional state	3.8
General disorders and administration site conditions Feeling abnormal	3.8
Gastrointestinal disorders Dysgeusia	3.4
Nervous system disorders Parosmia	3.0
Gastrointestinal disorders Nausea	2.8
Ear and labyrinth disorders Vertigo	2.4
Nervous system disorders Headache	2.3
Skin and subcutaneous tissue disorders Rash erythematous	2.1
Skin and subcutaneous tissue disorders Pruritus	1.6
Cardiac disorders Chest pain	1.1
Scotoma	1.1

System Organ Classification (SOC)

	Relative Frequency (%)
Skin and subcutaneous tissue disorders	23.42
Immune system disorders	12.4
Respiratory, thoracic and mediastinal disorders	10.17
General disorders and administration site conditions	10.07
Nervous system disorders	6.82
Cardiac disorders	6.81
Gastrointestinal disorders	6.41
Vascular disorders	6.05
Injury, poisoning and procedural complications	3.51
Renal and urinary disorders	2.41
Eye disorders	2.27
Investigations	2.01
Musculoskeletal and connective tissue disorders	2.01

IODIXANOL


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70